Glenmark has been operating in the Latin American region since early 1990s. This was primarily by way of exporting branded formulations to Caribbean markets. It was only in 2004 when the organization began to increase focus in this high-potential region through an acquisition in Brazil, the largest pharmaceutical market in the region. Presently the company operates in 12 markets in this region. Brazil is the largest subsidiary for the region and the other key focus markets are Mexico, Peru, Venezuela and Ecuador. The region has grown by a compounded average growth rate of 28 % for the last three years. Over 250 products are sold in the region.
|
|
Therapy Segments |
|
|
The Key Therapy segments for this region are
Dermatology
Respiratory
Gynaecology
Oncology
|
|
|
Key Brands |
|
Some of the key brands for Brazil are :
Adacne Clin
Adacne
Saciette
Ureativ
Fisioativ
Demelan
Sunderm
|
|
Some of the key brands for Latam are :
Deriva C
Deriva
Glevo
Canditral
Relcer
Esoz
Ketoplus
|
|
|
Acquisitions |
|
|
Brazil : Glenmark made its entry into the Brazilian market by acquiring of Klinger Laboratories in 2004. At the time of acquisition, Klinger had over 20 products registered and marketed in the country. It also had a manufacturing facility in Sao Bernardo do Campo in Greater Sao Paulo, Brazil.
|
|
